Sugammadex

Active ingredient: Sugammadex Sodium

In short: Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.

Forms & strengthsSugammadex injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion. Sugammadex injection is available as follows: 200 mg/2 mL (100 mg/mL) in a single-dose vial for bolus injection 500 …
LabelShandong New Time Pharmaceutical Co., Ltd.
Label updatedOct 08, 2026

What is Sugammadex used for?

Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.

Sugammadex dosage

Sugammadex injection dosing is based on actual body weight.

Sugammadex injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents.

Doses and timing of sugammadex administration should be based on monitoring for twitch responses and the extent of spontaneous recovery that has occurred.

Administer sugammadex intravenously as a single bolus injection. The bolus injection may be given over 10 seconds, into an existing intravenous line. Sugammadex injection has only been administered as a single bolus injection in clinical trials.

From the time of sugammadex administration until complete recovery of neuromuscular function, monitor the patient to assure adequate ventilation and maintenance of a patent airway. Satisfactory recovery should be determined through assessment of skeletal muscle tone and respiratory measurements in addition to the response to peripheral nerve stimulation.

The recommended dose of sugammadex does not depend on the anesthetic regimen.

Preparation of dilution for pediatric use:

Sugammadex 100 mg/mL may be diluted to a concentration of 10 mg/mL, using 0.9% sodium chloride injection, USP, to increase the accuracy of dosing in the pediatric population.

To prepare the required dose, aseptically transfer all the contents of the 2 mL vial of sugammadex 2­mL single-dose vials containing 200 mg sugammadex (100 mg/mL) to a bottle (or intravenous bag) containing 18 mL of 0.9% sodium chloride injection, to achieve a final concentration of 10 mg/mL sugammadex.

Sugammadex injection is a single-dose sterile solution without preservatives. Discard any unused portion from the vial.

If not used immediately, the diluted solution can be stored up to 48 hours refrigerated (5°C; 41°F) or at room temperature (25°C; 77°F).

Sugammadex can be used to reverse different levels of rocuronium- or vecuronium-induced neuromuscular blockade.

For rocuronium and vecuronium:

A dose of 4 mg/kg sugammadex is recommended if spontaneous recovery of the twitch response has reached 1 to 2 post-tetanic counts (PTC) and there are no twitch responses to train-of-four (TOF) stimulation following rocuronium- or vecuronium-induced neuromuscular blockade

.

A dose of 2 mg/kg sugammadex is recommended if spontaneous recovery has reached the reappearance of the second twitch (T

2) in response to TOF stimulation following rocuronium- or vecuronium-induced neuromuscular blockade

.

For rocuronium only:

A dose of 16 mg/kg sugammadex is recommended if there is a clinical need to reverse neuromuscular blockade soon (approximately 3 minutes) after administration of a single dose of 1.2 mg/kg of rocuronium. …

How to take Sugammadex — instructions & advice from the label

Advise females of reproductive potential using hormonal contraceptives that sugammadex injection may reduce the contraceptive effect. Instruct females to use an additional, non-hormonal method of contraception for the next 7 days following sugammadex injection administration

.

Warnings & precautions

Do not take this medicine if: Sugammadex is contraindicated in patients with known hypersensitivity to sugammadex or any of its components. Hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex

.

Clinicians should be prepared for the possibility of drug hypersensitivity reactions (including anaphylactic reactions) and take the necessary precautions

.

Potentially serious hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with sugammadex. The nature and frequency of anaphylaxis and hypersensitivity associated with sugammadex administration were evaluated in a randomized, double-blind, placebo-controlled, parallel-group, repeat-dose study in which 375 subjects were randomized to receive 3 doses of sugammadex IV with a 5-week washout period: 151 subjects received 4 mg/kg, 148 received 16 mg/kg and 76 received placebo. The frequency of anaphylaxis for the 299 healthy volunteers treated with intravenous sugammadex was 0.3% (n=1 in the sugammadex 16 mg/kg group on the first dose). Signs and symptoms included conjunctival edema, urticaria, erythema, swelling of the uvula and reduction in peak expiratory flow within 5 minutes of dose administration. The most common hypersensitivity adverse reactions reported were nausea, pruritus and urticaria and showed a dose response relationship, occurring more frequently in the 16 mg/kg group compared to the 4 mg/kg and placebo groups.

Anaphylaxis has also been reported in the post-marketing setting, including at doses less than 16 mg/kg. …

Sugammadex side effects

The following serious adverse reactions are described elsewhere in the labeling:

Anaphylaxis and Hypersensitivity

Marked Bradycardia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adult Patients

The data described below reflect 2914 subjects exposed to 2, 4, or 16 mg/kg sugammadex and 544 to placebo in pooled Phase 1-3 studies. The population was 18 to 92 years old, 47% male and 53% female, 34% ASA (American Society of Anesthesiologists) Class 1, 51% ASA Class 2, and 14% ASA Class 3, and 82% Caucasian. Most subjects received a single dose of sugammadex 2 mg/kg or 4 mg/kg.

Adverse reactions reported in ≥10% of patients at a 2, 4, or 16 mg/kg sugammadex dose with a rate higher than the placebo rate are: vomiting, pain, nausea, hypotension, and headache.

All adverse reactions occurring in ≥2% of subjects treated with sugammadex and more often than placebo for adult subjects who received anesthesia and/or neuromuscular blocking agent in pooled Phase 1 to 3 studies are presented in Table 2. …

Drug interactions

The information reported in sections 7.2 – 7.4 is based on binding affinity between sugammadex and other drugs, preclinical experiments, clinical studies and simulations of a pharmacokinetic-pharmacodynamic (PK-PD) model. Based on these considerations, no clinically significant pharmacodynamic interactions with other drugs are expected, with the exception of toremifene and hormonal contraceptives.

Toremifene

For toremifene, which has a relatively high binding affinity for sugammadex and for which relatively high plasma concentrations might be present, some displacement of vecuronium or rocuronium from the complex with sugammadex could occur. The recovery to TOF ratio to 0.9 could therefore be delayed in patients who have received toremifene on the same day of surgery.

In vitrobinding studies indicate that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, the administration of a bolus dose of sugammadex is considered to be equivalent to missing dose(s) of

oralcontraceptives containing an estrogen or progestogen. …

About this medicine

Sugammadex injection, for intravenous use, contains sugammadex sodium, a modified gamma cyclodextrin chemically designated as

6

A, 6

B, 6

C, 6

D, 6

E, 6

F, 6

G, 6

H-Octakis-S-(2-carboxyethyl) 6

A, 6

B, 6

C, 6

D, 6

E, 6

F, 6

G, 6

H-octathio-γ-cyclodextrin sodium salt

(1:8) with a molecular weight of 2178.01. The structural formula is:

Sugammadex injection is supplied as a sterile, non-pyrogenic aqueous solution that is clear, colorless to slightly yellow-brown for intravenous injection only. Each mL contains 100 mg sugammadex, which is equivalent to 108.8 mg sugammadex sodium. The aqueous solution is adjusted to a pH of between 7 and 8 with hydrochloric acid and/or sodium hydroxide. The osmolality of the product is between 300 and 500 mOsmol/kg.

Sugammadex may contain up to 7 mg/mL of the mono OH-derivative of sugammadex

. This derivative is chemically designated as

6

A, 6

B, 6

C, 6

D, 6

E, 6

F, 6

G-Heptakis-S-(2-carboxyethyl)-6

A, 6

B, 6

C, 6

D, 6

E, 6

F, 6

G-heptathio- γ -cyclodextrin sodium salt

(1:7) with a molecular weight of 2067.90. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 56400560-a2df-4126-b424-9e4b91e53a8b. Read the full official label on DailyMed.